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Objectives The purpose of this study was to determine whether a heart failure (HF) management strategy using continuous
intracardiac pressure monitoring could decrease HF morbidity.
Background Patients with HF may experience frequent decompensations that require hospitalization despite intensive treat-
ment and follow-up.
Methods The COMPASS-HF (Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Fail-
ure) study was a prospective, multicenter, randomized, single-blind, parallel-controlled trial of 274 New York
Heart Association functional class III or IV HF patients who received an implantable continuous hemodynamic
monitor. Patients were randomized to a Chronicle (Medtronic Inc., Minneapolis, Minnesota) (n  134) or control
(n  140) group. All patients received optimal medical therapy, but the hemodynamic information from the
monitor was used to guide patient management only in the Chronicle group. Primary end points included free-
dom from system-related complications, freedom from pressure-sensor failure, and reduction in the rate of HF-
related events (hospitalizations and emergency or urgent care visits requiring intravenous therapy).
Results The 2 safety end points were met with no pressure-sensor failures and system-related complications in only 8% of the
277 patients who underwent implantation (all but 4 complications were successfully resolved). The primary efficacy
end point was not met because the Chronicle group had a nonsignificant 21% lower rate of all HF-related events com-
pared with the control group (p 0.33). A retrospective analysis of the time to first HF hospitalization showed a 36%
reduction (p  0.03) in the relative risk of a HF-related hospitalization in the Chronicle group.
Conclusions The implantable continuous hemodynamic monitor-guided care did not significantly reduce total HF-related
events compared with optimal medical management. Additional trials will be necessary to establish the clinical
benefit of implantable continuous hemodynamic monitor-guided care in patients with advanced HF. (J Am Coll
Cardiol 2008;51:1073–9) © 2008 by the American College of Cardiology Foundation
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The COMPASS-HF Study Results March 18, 2008:1073–9Advanced heart failure (HF) is
characterized by frequent symp-
toms and hospitalizations result-
ing from fluid accumulation (1).
To decrease the frequency of such
events, patients must be closely
monitored to detect changes in
fluid volume status that may war-
rant modifying therapy. How-
ever, current volume assessment
methods, such as physical exam-
ination or chest radiography, of-
ten correlate poorly with true
volume status in patients with
chronic HF (2,3). Even when
fluid status is correctly assessed
in the clinic, significant changes
ften occur in the ambulatory setting, where reliable infor-
ation pertaining to volume status is lacking. Early signs of
ecompensation are often missed, along with the opportu-
ity for timely intervention.
See page 1080
totally implantable continuous hemodynamic monitor
ICHM) has been developed for outpatient HF manage-
ent. The device (Chronicle, Medtronic Inc., Minneapolis,
innesota) continuously measures and stores hemodynamic
nformation that can be reviewed remotely. Chronic studies
omparing intracardiac pressure measurements recorded by
he ICHM with those obtained by a Swan-Ganz catheter
ave found the system to be safe, well tolerated, accurate,
nd stable over time (4–6). Early experiences using ICHM
nformation in clinical practice supported the use of intra-
ardiac pressures to manage volume status (7) and reduce
F-related hospitalizations (8).
The COMPASS-HF (Chronicle Offers Management to
atients with Advanced Signs and Symptoms of Heart
ailure) trial was a randomized, single-blind, parallel-
ontrolled trial designed to determine the clinical impact of
n ICHM-based management strategy in patients with
dvanced HF already receiving optimal medical care.
ethods
atients. Patients were eligible for enrollment in the study
f they were at least 18 years old; had New York Heart
ssociation (NYHA) functional class III or IV HF (regard-
ess of ejection fraction); were managed in centers with an
dvanced HF program (participating investigators, sites,
nd coordinators are listed in the Online Appendix); re-
eived optimized standard medical therapy (angiotensin-
onverting enzyme inhibitor or angiotensin receptor
locker, and a beta-blocker; all medications as tolerated) for
Abbreviations
and Acronyms
CRT  cardiac
resynchronization therapy
EF  ejection fraction
ePAD  estimated
pulmonary artery diastolic
pressure
HF  heart failure
ICD  implantable
cardioverter-defibrillator
ICHM  implantable
continuous hemodynamic
monitor
NYHA  New York Heart
Associationt least 3 months before enrollment; and had at least 1 aF-related hospitalization or emergency department visit
ecessitating intravenous treatment (e.g., diuretic adminis-
ration) within the previous 6 months. Patients were ex-
luded from the study if they had severe chronic obstructive
ulmonary or severe restrictive airway disease; pulmonary
rterial hypertension; a major cardiovascular event (other
han hospitalization) within 3 months before enrollment;
nown atrial or ventricular septal defects; tricuspid or
ulmonary stenosis; mechanical right heart valves; a severe,
oncardiac condition limiting 6-month survival; serum
reatinine 3.5 mg/dl or chronic renal dialysis; were likely
o undergo cardiac transplantation within 6 months of
andomization; were receiving continuous positive inotropic
herapy; were presently implanted with an incompatible
acemaker or implantable cardioverter-defibrillator (ICD);
ere receiving cardiac resynchronization therapy (CRT)
hat had not achieved optimal programming for 3 months;
r were of childbearing age without reliable contraceptive
easures. The institutional review board of each participat-
ng center approved the study protocol, and all patients
rovided written informed consent.
Patients with a preserved left ventricular ejection fraction
EF 50%) were included in the study for the following
easons: 1) HF patients with preserved EF account for
pproximately 50% of all HF hospitalizations (1); 2) the
orbidity of such patients is comparable to that of HF
atients with depressed EF, with a 50% 6-month re-
ospitalization rate in both groups; and 3) HF patients with
reserved EF have been difficult to manage (9,10).
tudy design and procedure. Patients who met the entry
riteria underwent the following baseline assessments: his-
ory and physical examination; chemistry profile; pulmonary
unction test; health care utilization in the 6 months before
mplantation; Minnesota Living with Heart Failure Quality
f Life Questionnaire; NYHA functional classification;
-min hall walk; echocardiogram; and 12-lead electrocar-
iogram. After initial evaluation, study participants under-
ent ICHM implantation, and if successful, were random-
zed for 6 months to the Chronicle or control group.
andomization schedules were created for patients based on
F (50% or 50%) for each center. Clinicians had access
o the hemodynamic information only in the Chronicle
roup. Beyond the 6-month randomization period, clini-
ians were granted full access to ICHM information in both
roups.
During follow-up, clinicians reviewed the hemodynamic
nformation of their Chronicle patients at least weekly to
etermine volume status. Patients were asked to chart daily
eights and to document any adjustments made in daily
edications. In addition, changes in patient symptoms and
edications were documented by the enrolling site. At 1, 3,
nd 6 months post-implantation, all study patients returned
or reassessment of their physical status, NYHA functional
lass, medications, health care use, and adverse events. At
he 3- and 6-month visits, the quality-of-life questionnaire
nd 6-min hall walk were repeated.
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March 18, 2008:1073–9 The COMPASS-HF Study ResultsAn independent Clinical Events Adjudication Commit-
ee, blinded to patients’ randomization assignment, adjudi-
ated all major events, including hospitalizations, emer-
ency department visits, and urgent clinic visits.
linding. The design of the COMPASS-HF trial was
ingle blind because clinicians needed to periodically review
atient-specific hemodynamic information and implement
ppropriate individual treatment plans in the Chronicle
roup. To maintain patient blinding during the randomized
ollow-up period, several measures were incorporated into
he study protocol. First, patients in both groups were asked
o transmit their ICHM information at least weekly. Sec-
nd, to ensure that nonblinded caregivers did not inadver-
ently disclose the patient’s randomization assignment, pre-
rafted standardized clinician communication scripts were
sed. These scripts included questions related to standard
F management (e.g., shortness of breath, weight gain),
ut did not include any reference to intracardiac pressures.
fter any telephone contact with patients (clinician-
nitiated or patient-initiated), clinicians completed a tele-
hone communication form. Third, because clinician review
f hemodynamic information was expected to increase the
requency of calls in the Chronicle group (e.g., change in
ressure that might warrant a medication change), pre-
etermined call schedules were generated for the control
atients. During the study, additional random call schedules
ere used in the control group to match the increased
requency of communications in the Chronicle group.
CHM system description. The ICHM system (Model
520, Medtronic) consists of: 1) a programmable device that
rocesses and stores information and is similar in appearance to
he pulse generator of a pacemaker; and 2) a transvenous lead
model 4328A, Medtronic) that has a sensor incorporated near
ts tip to measure intracardiac pressure. The implantation
rocedure is similar to that of a single-lead pacemaker system,
ith the device positioned subcutaneously in the pectoral area
nd the lead positioned transvenously in the right ventricular
utflow tract or septum.
The ICHM is capable of continuously monitoring and
toring heart rate, body temperature, patient activity, right
entricular systolic and diastolic pressure, maximal positive
nd negative rate of change in right ventricular pressure
dP/dt), right ventricular pre-ejection and systolic time
ntervals, and estimated pulmonary arterial diastolic pressure
ePAD) (11). The ePAD is defined as the right ventricular
ressure at the time of pulmonary valve opening, which
ccurs at the time of maximal dP/dt (7,11,12). A strong
orrelation (r  0.84) has been shown to exist between
PAD and actual pulmonary artery pressures measured
nder a variety of physiological conditions (5,12,13).
Because the ICHM records absolute pressure, all pressure
ata were corrected for barometric pressure using a small
xternal pressure reference device (model 2955HF, Medtronic)
arried by the patient.
CHM data generation and flow. The ICHM measures
ll pressure parameters on a beat-to-beat basis, but ulti-ately commits to memory a smaller dataset based on a
rogrammable storage interval, most often set to approxi-
ately 8.5 min. For each pressure parameter, the median as
ell as the sixth and 94th percentiles of all measurements
aken within this pre-set time interval are determined and
tored. All patients were instructed to transmit information
rom the ICHM at least weekly using a home monitor that
nterrogates the device via a standard handheld radio fre-
uency wand and transmits the data through a telephone
ine to a secure server. Clinicians could access the data
ransmitted by their patients on the ICHM Web site using
onventional Internet access.
CHM data review and use. Hemodynamic data were
vailable for clinical management only in the Chronicle
roup. Review of the pressure information occurred at least
nce per week, usually in conjunction with data transmis-
ion from the patient’s home. The Web site automatically
oncatenates new data received from the device with data
rom previous transmissions and provided visual represen-
ation of the data in the form of trends over time (Figure 1).
he ultimate goal of ICHM data review was to determine
he patient’s pressure status remotely and intervene appro-
riately before an HF-related event.
nd points and statistical analysis. For the primary effec-
iveness end point, we hypothesized that the Chronicle
roup would have a 30% lower rate of combined HF-related
vents (hospitalizations, emergency department and urgent
linic visits requiring intravenous therapy) compared with
he control group. The event rate in the control group was
stimated to be 1.2 per 6 patient-months, determined from
revious ICHM studies and other published HF trials
14–17). A cumulative randomized follow-up of 1,354
atient-months was required to show significance in event
ates between the 2 groups with 80% power (alpha  0.05).
total of 274 patients were randomized to satisfy sample
ize requirements and attrition assumptions. The primary
Figure 1 Two Trends Available on the Chronicle Web Site
One-month trends of right ventricular (RV) systolic and estimated pulmonary
artery diastolic (ePAD) pressures.
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The COMPASS-HF Study Results March 18, 2008:1073–9ffectiveness end point was analyzed using a negative bino-
ial regression (18). Additionally, a retrospective analysis of
he relative risk of a HF hospitalization was performed
sing a Cox proportional hazards regression model.
For the primary safety end points, we hypothesized that
t 6 months, the freedom from system-related complica-
ions would be80%, and the freedom from pressure sensor
ailure would be 90%. A system-related complication was
efined as any adverse event that was related to the system
ICHM and pressure sensor lead) and was either treated
ith invasive means or resulted in the death of a patient, the
xplant of the device or caused permanent loss of significant
unction of the system. Because the integrity of the pressure
ata is related to the performance of the pressure sensor
ead, it was deemed important to designate pressure sensor
ead failure as a separate safety end point. The sample size
equirement for testing the primary effectiveness end point
1,354 patient months) was more than adequate to test both
rimary safety end points. The primary safety end points
ere analyzed using the Kaplan-Meier method.
An independent Data Monitoring Committee reviewed
ll of the safety and effectiveness data. Group sequential
ethods were used to create predetermined decision bound-
ries using O’Brien and Fleming shape parameters (19).
he level of significance for the final analysis was 0.048 for
he primary efficacy end point and 0.049 for the primary
afety end points.
esults
total of 301 patients were enrolled in the study. Twenty-
our patients exited the study before device implantation
ttempt: 2 patients died before scheduled implant, 7 with-
rew consent, 6 were withdrawn by the investigator, 6 had
tudy entrance criteria violations, and 3 patients could not
Figure 2 Patient Enrollment and Disposition
Flow chart details the patient enrollment in the study. LVEF  left ventricular ejectndergo implantation because of anatomical considerations.
he remaining 277 patients underwent an implant attempt,
ith 274 patients (99%) with successful implantations. The
unsuccessful implantations were caused by entanglement
f the lead in the tricuspid valve, complete heart block, and
nability to gain venous access. These 274 patients were then
andomized to either the Chronicle (n  134) or control
roup (n  140) (Fig. 2). Clinical characteristics of ran-
omized patients were well balanced between the 2 groups
Table 1), with the exception of baseline diuretic use (93%
n the Chronicle vs. 99% in the control group). However, by
ay 17 of randomization, diuretic use was 99% in both
roups.
Of the 274 randomized patients, 245 completed their
-month follow-up, accruing 1,620 patient-months of ran-
omized follow-up. Of the 29 patients who exited the study
uring the randomization period, 16 were in the Chronicle
roup (13 patients died, 2 patients withdrew consent, and 1
atient transferred care), and 13 were in the control group
11 patients died, 1 was lost to follow-up, and 1 patient was
ithdrawn because of lead dislodgement). Implementation
f the study’s rigorous blinding protocols, as described
arlier, resulted in an equivalent average number of tele-
hone calls between patients and clinics over the 6-month
andomization period (24.7 calls/patient in both groups).
rimary safety end points. Both primary safety end points
ere met. Of the 277 patients in whom an implantation was
ttempted, 23 patients experienced a total of 24 complica-
ions for a complication-free rate of 91.5% (lower 1-sided
5% confidence bound of 88.7%). All but 1 of the 24
omplications were related to the lead. Of the 23 lead-
elated events, 15 were lead dislodgements, all of which
ere either repositioned or replaced. The 1 nonlead-related
omplication was caused by premature battery failure, which
ction.ion fra
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March 18, 2008:1073–9 The COMPASS-HF Study Resultsas resolved by an ICHM system replacement. Overall, 20
f the 24 (83%) system-related complications were success-
ully resolved and resulted in a fully functional ICHM
ystem. No sensor failures occurred in the 274 randomized
atients.
During the initial implantation, there were 6 procedure-
elated and 6 device-related complications in 12 patients
hat prolonged the initial hospitalization by a total of 10
ays in 6 patients. After implantation, there were 11
ospitalizations for device-related complications and 4 hos-
italizations for procedure-related complications that re-
ulted in a total of 40 additional hospitalization days in 13
f the 274 successful implantation patients.
rimary efficacy end point. There were 84 HF-related
vents in 44 patients in the Chronicle group, and 113 in 60
atients in the control group, for an event rate of 0.67 and
Figure 3 Distribution of All Heart Failure–Related Events
Event rates were compared with a negative binomial regression model.
atient Baseline Characteristics
Table 1 Patient Baseline Characteristics
Chronicle
(n  134)
Control
(n  140) p Value
Age (yrs), mean  SD 58  14 58  13 0.75
Gender (% female) 34 36 0.80
Ethnicity (% Caucasian) 73 80 0.20
Etiology (% ischemic) 47 44 0.72
New York Heart Association functional
class (% class III)
84 87 0.49
Prior heart failure events (mean SD)* 1.8  1.3 1.9  1.3 0.27
Concomitant devices (%) 42 37 0.46
Diuretic use (%) 93 99 0.01
ACE-I or ARB use (%) 85 81 0.52
Beta-blocker use (%) 83 81 0.76
CE-I  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker.
Six months before implantation..85 per 6 patient-months, respectively (Fig. 3). The pri-
ary efficacy end point was not met because the 21%
eduction in the rate of HF-related events in the Chronicle
roup was not statistically significant (p  0.33). Nonhos-
italization HF-related events were equally rare in both the
hronicle and control groups (10 vs. 11 emergency depart-
ent visits and 2 vs. 3 urgent care visits, respectively).
pecific attention was also paid to events such as hypovo-
emia, which could occur because of overdiuresis. There
ere 6 events in 6 patients in the Chronicle group caused by
ypovolemia, compared with 10 events in 9 patients in the
ontrol group.
etrospective efficacy analysis. A retrospective efficacy
nalysis was performed using the time to first HF-related
ospitalizations after randomization (Fig. 4). During the
andomized period, 37 patients in the Chronicle group were
ospitalized for HF, compared with 57 patients in the
ontrol group (hazard ratio 0.64, 95% confidence interval
.42 to 0.96, p  0.03). This represented a 36% reduction
n the relative risk of an HF-related hospitalization in the
hronicle group. The reduction in the relative risk of an
F-related hospitalization was comparable in the groups
ith EF 50% and 50%.
iscussion
reatment of patients with HF has improved dramatically
ver the last 2 decades. Angiotensin-converting enzyme
nhibitors, angiotensin receptor blockers, beta-blockers, al-
osterone antagonists, and more recently CRT and ICDs,
ave all been shown to improve patient outcomes (20).
espite the progress in these therapies, the number of
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The COMPASS-HF Study Results March 18, 2008:1073–9ospitalizations for worsening HF continues to increase
21). Symptoms associated with hospitalization are most
ften attributable to increased filling pressures and the
esultant pulmonary and systemic venous congestion (22).
o reduce HF hospitalizations, improved strategies for
utpatient monitoring and fluid management are urgently
eeded. There has been concern, however, that knowledge
f ventricular filling pressures may lead to intensification of
iuretic therapy and an increase in events attributable to
elative hypovolemia.
The COMPASS-HF study was a unique study that
mplemented and tested a novel HF management strategy
sing objective ICHM-derived information on a patient’s
ynamic intracardiac pressure status in the ambulatory
etting. It is important to recognize that this trial evaluated
novel management strategy using existing evidence-based
herapies for HF, rather than a new therapeutic modality.
Although there was 21% reduction in the total event rate
n the Chronicle group compared with the control group,
he difference was not significant and the primary efficacy
nd point was not met (Fig. 3). It is possible that the study
as underpowered to show a significant difference in event
ates between the 2 groups. The sample size was estimated
ased on an event rate of 1.2 per 6 patient-months in the
ontrol group, but the actual event rate in the control group
as only 0.85 per 6 patient-months. This lower event rate
an be partially attributed to the intensive contact schedule
etween patients and clinics in the control group (almost
nce per week) that matched the contact schedule observed
n the Chronicle group. Because frequent patient contact
ith HF management teams reduces hospitalizations
Figure 4 Kaplan-Meier Curves of Survival
Free From an HF-Related Hospitalization
Hazard ratios (HRs) are from a Cox
proportional hazards regression model. HF  heart failure.23,24), this increased level of interaction likely contributed Co the lower than expected event rate observed in the control
roup and reduced the power of the study to show a
ignificant benefit of the ICHM.
Despite the lack of a significant reduction in the com-
ined event rate in the Chronicle group, a retrospective
nalysis showed that there was a 36% reduction in the
elative risk of a first HF-related hospitalization (Fig. 4),
nd this suggests the ICHM may have some clinical
alue. This analysis was based on a subset of total
F-related events (48% were first hospitalizations), and
his may partially account for the difference between this
nd point and the primary end point. Although the time
o first HF-related hospitalization was not a pre-specified
nd point, this end point has been used in other HF trials
25,26).
Until now, HF management in the ambulatory setting
as been limited to clinical assessment during outpatient
isits and the evaluation of symptoms and weight changes as
eported by the patient from home. However, the ICHM
rovides additional hemodynamic information that may
mprove HF management. Managing patients using the
CHM information included defining an optimal pressure
ange for each patient. When hemodynamic data deviated
rom this range, therapy was adjusted with the goal of
estoring pressure to the optimal range. Indeed, patients in
he Chronicle group had 28% more adjustments in their
herapies than patients in the control group, despite an
quivalent frequency of patient contacts to evaluate symp-
oms and weight changes. The majority of these changes
ere in diuretic doses, which were changed 54% more often
n the Chronicle group. Although these changes in diuretic
oses did not significantly reduce the rate of all HF-related
vents, there was also no increase in events that might be
ttributed to overdiuresis in the Chronicle group.
Given the amount of information provided by the
CHM, there is the question of training and widespread
doption of this technology. A learning curve is to be
xpected in association with the routine integration of
ntracardiac pressures into clinical practice. Moreover, the
CHM generates large amounts of data in each patient that
equire review. However, the trial experience showed that
ven high-enrolling centers were able to successfully manage
he data during the required follow-up period and beyond.
ome participating centers had staffing capacity that may
ot reflect the mainstream clinics caring for HF patients,
nd this may have facilitated management of the ICHM
ata. Hopefully, future data management tools, including
utomated algorithms and potentially third-party monitor-
ng services, may alleviate some of these concerns.
tudy limitations. In the COMPASS-HF study, clini-
ians were required to use the ICHM information to guide
atient-specific care; thus, a double-blind design was not
ossible. Because all patients received a device to control for
potential placebo effect, the study lacked a concurrent
ontrol arm without an implanted device. Because the
OMPASS-HF study was conducted primarily at sites
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March 18, 2008:1073–9 The COMPASS-HF Study Resultsith dedicated HF programs, the ICHM experience has not
et been generalized to the community setting. Further-
ore, it is important to recognize that all patients in both
roups required at least 1 hospitalization day to implant the
CHM.
onclusions
n patients with moderate to severe HF, the addition of an
CHM to optimal medical management did not signifi-
antly reduce the rate of all HF-related events. Additional
rials will be necessary to establish the clinical benefit of
CHM-guided care in this patient population.
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